Compare Lucid Group Inc (LCID) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lucid Group Inc trades at $3.81 (market cap $1.51B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 84.5× Lucid Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LCID | VRTX | |
|---|---|---|
Market Cap | $1.51B | $127.55B |
Volume | 12,333,745 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $557.96 |
52-Week Low | $3.82 | $407.37 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $4.40B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.79, down 2.57% on the day, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including significant losses, negative profit margins, and cash burn. Recent news highlights management's focus on cost savings and strategic partnerships while delaying key product launches like the Cosmos SUV.
The outlook remains challenging with persistent losses and high cash burn requiring additional financing. Analyst consensus is cautious with only 13% buy ratings and a $7.60 price target representing potential upside. Key risks include execution delays, competitive pressure, and potential dilution from future capital raises.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
